EP08.02-128 Long Term Efficacy of SNK01 Plus Pembrolizumab for NSCLC: Expanded Observation from a Phase I/II A Randomized Controlled Trial

H. Park, J.S. Jung, Y.M. Kim, Y. Kang, W. Ji, J.C. Lee,C.-M. Choi

Journal of Thoracic Oncology（2022）

引用 0|浏览3

暂无评分

摘要

Previous NK cell role with pembrolizumab for advanced NSCLC showed better efficacy than pembrolizumab alone. However, the prolonged effect of NK cells with pembrolizumab was not evaluated yet. This study evaluates the role of NK cells with pembrolizumab for more than 2 years from a previous randomized controlled trial.

查看译文

关键词

snk01 plus pembrolizumab,long term efficacy,nsclc,randomized controlled trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要